Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Shape the $400 Billion Biologics War
The Fork in the Road That Determines Billions When a drug company files for FDA approval of a new medicine, […]
Find Expired Drug Patents Before Your Competitors Do
A complete operational guide to locating abandoned and lapsed pharmaceutical patents for generic market entry The Money Is in the
Find Expired Drug Patents Before Your Competitors Do Read Post »
Win the Market After the Patent Falls: ANDA and Suitability Petitions as Strategic Weapons
The Moment Everyone Prepares for and Nobody Fully Survives The day a blockbuster drug’s core patent expires is circled on
AI Is Your Drug’s New KOL — and You’re Not Tracking It
How chatbots became the most influential prescribing influencers in pharma, what happens when they get it wrong, and the monitoring
AI Is Your Drug’s New KOL — and You’re Not Tracking It Read Post »
Find the Money Before the Patent Dies: How to Identify Out-Licensing Targets Near Drug Patent Expiry — and Capture Value That Most Companies Leave on the Table
The math is brutal and straightforward. A branded drug generating $800 million annually can lose 80 to 90 percent of
Know the Dates: How to Forecast Drug Patent Expiry by Country for Smarter Portfolio Planning
The Calendar Is Your Competitive Weapon Every pharmaceutical company has a patent expiry problem. Not because patents expire — that
The Manufacturing Moat: Why Process Patents Are the Most Undervalued Defense Against Generic Entry
The Hierarchy Problem in Pharmaceutical IP Every pharmaceutical patent portfolio has a hierarchy, whether the company managing it acknowledges one
Don’t Get Burned: 3 Critical Patent Due Diligence Steps Before Investing in Biotech IPOs
The IPO Trap That Costs Investors Billions Biotech IPOs are uniquely dangerous investments, and not for the reasons most investors
Don’t Get Burned: 3 Critical Patent Due Diligence Steps Before Investing in Biotech IPOs Read Post »
5 Costly Mistakes Companies Make When Modeling Biosimilar Entry Windows
The Model That Cost $2 Billion In the spring of 2018, a major integrated health system’s pharmacy benefit function projected
5 Costly Mistakes Companies Make When Modeling Biosimilar Entry Windows Read Post »
